Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TASP1 | Q9H6P5 | 1/20 | 0.62 |
| ▸ | CASP1 | P29466 | 4/20 | 0.56 |
| ▸ | CASP3 | P42574 | 3/20 | 0.56 |
| ▸ | CASP9 | P55211 | 3/20 | 0.56 |
| ▸ | CASP4 | P49662 | 2/20 | 0.56 |
| ▸ | CASP5 | P51878 | 2/20 | 0.56 |
| ▸ | CASP6 | P55212 | 2/20 | 0.56 |
| ▸ | CASP8 | Q14790 | 2/20 | 0.56 |
| ▸ | CASP10 | Q92851 | 2/20 | 0.56 |
| ▸ | MAGI3 | Q5TCQ9 | 1/20 | 0.46 |
| ▸ | ENPEP | Q07075 | 7/20 | 0.44 |
| ▸ | CASP7 | P55210 | 2/20 | 0.43 |
| ▸ | GZMB | P10144 | 2/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5746872 | 0.93 | TASP1 (0.61) | TASP1CASP1CASP3CASP9CASP4 | |
| SCHEMBL20257260 | 0.93 | TASP1 (0.53) | TASP1CASP1CASP3CASP9CASP4 | |
| SCHEMBL20257263 | 0.93 | TASP1 (0.53) | TASP1CASP1CASP3CASP9CASP4 | |
| SCHEMBL23133164 | 0.90 | TASP1 (0.50) | TASP1CASP1CASP3CASP9CASP4 | |
| SCHEMBL29974620 | 0.86 | MAGI3 (0.56) | TASP1CASP1CASP3CASP9CASP4 | |
| SCHEMBL29974746 | 0.86 | MAGI3 (0.56) | TASP1CASP1CASP3CASP9CASP4 | |
| SCHEMBL23133165 | 0.85 | TASP1 (0.52) | TASP1CASP1CASP3CASP9CASP4 | |
| SCHEMBL23924919 | 0.85 | TASP1 (0.52) | TASP1CASP1CASP3CASP9CASP4 | |
| SCHEMBL20257131 | 0.85 | TASP1 (0.52) | TASP1CASP1CASP3CASP9CASP4 | |
| SCHEMBL23132679 | 0.85 | TASP1 (0.52) | TASP1CASP1CASP3CASP9CASP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030055103-A1 | Utilization of achyrocline satureoides (\"Marcela\") extracts and liposomal preparations of natural and semi-synthetic flavonoids for the prevention and treatment of the consequences of stroke and neurodegenerative diseases | HEINZEN HORACIO (UY) | 2003-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055103-A1 | Utilization of achyrocline satureoides (\"Marcela\") extracts and liposomal preparations of natural and semi-synthetic flavonoids for the prevention and treatment of the consequences of stroke and neurodegenerative diseases | ACHE, KYNU, NLN | TASP1 859/4885CASP1 559/4885CASP3 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.